Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Gov't Should Foster More Researchers to Stimulate Drug Discovery in Japan: Lawmaker Ebata
July 5, 2010
- Japan Considers Introduction of IFRS
July 5, 2010
- Banyu/Ono Apply for Combinational Use of Sitagliptin and Alfa GI
July 5, 2010
- MBL, MCM Tie Up for Marketing of STACIA, Dedicated Reagents
July 5, 2010
- Takeda to Create Sales Subsidiary in South Korea
July 5, 2010
- Kowa Licenses Livalo to Abbott in Australia, New Zealand
June 28, 2010
- 2 Sets of GLs for Development of Vaccines Issued
June 28, 2010
- Meiji Seika Begins PIIa Study for Fibromyalgia with Mirtazapine
June 28, 2010
- Asahi Kasei Pharma Licenses Zoledronic Acid from Novartis
June 28, 2010
- Continued Treatment with Strattera Now Permitted after 18th Anniversary
June 28, 2010
- SymBio Licenses Lupuzor from Cephalon
June 28, 2010
- Takeda Terminates Collaboration with CanBas for CBP501
June 28, 2010
- LTT Bio-Pharma's IPF Drug Midismase Obtains Orphan Status
June 28, 2010
- JPMA Releases List of Unapproved Drugs/Indications without Development Sponsor
June 28, 2010
- GSK, Yoshitomi to Terminate Copromotion of Paxil in July
June 28, 2010
- Additional Indication Approved for Actemra in Europe: Roche
June 28, 2010
- NBI, Astellas Disagree With Meta-Analysis on Safety of Telmisartan
June 28, 2010
- Pfizer Creates Rare Disease Research Unit
June 28, 2010
- Korosho to Increase Transparency of NDA Review Process: Mr Nagatsuma
June 28, 2010
- Afinitor Extends PFS in Advanced pNET Patients in PIII: Novartis
June 28, 2010
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…